Generic GLP-1 drugs now widely available across Canada: what patients need to know

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Generic and compounded versions of GLP-1 (glucagon-like peptide-1) receptor agonists, the class of drugs that includes semaglutide (sold in Canada as Ozempic for type 2 diabetes and Wegovy for chronic weight management) and liraglutide (sold as Victoza and Saxenda), are now widely available at Canadian pharmacies and through online prescribing platforms, following years of brand-name shortages and steep out-of-pocket costs that put these medications out of reach for many patients. For Canadians living with obesity or type 2 diabetes, this shift means more options, but it also means navigating a fragmented coverage system and a drug class that carries real risks alongside its well-documented benefits.

The arrival of lower-cost alternatives matters because the brand-name versions have been financially inaccessible for a large share of patients. Wegovy, for example, has carried a list price of roughly CAD $400 to $500 per month in Canada, and provincial pharmacare programs have been slow to add it to their formularies. Ozempic has fared somewhat better on coverage for patients with type 2 diabetes, but its use for weight management alone has generally not been covered under OHIP (Ontario Health Insurance Plan), RAMQ (Régie de l'assurance maladie du Québec), MSP (Medical Services Plan in British Columbia), or AHCIP (Alberta Health Care Insurance Plan). The availability of generics and compounded semaglutide through licensed Canadian compounding pharmacies changes that calculus, though it also raises questions about quality, dosing consistency, and regulatory oversight.

What this means in Canada

Health Canada has not issued a formal approval for a generic tablet or injectable version of semaglutide as of November 2026, though it has authorized some biosimilar pathways and has been monitoring the compounding pharmacy market closely. Compounded semaglutide, mixed by licensed pharmacies from bulk active pharmaceutical ingredient, occupies a grey zone: it is legal under Canada's Food and Drugs Act when prepared by a licensed compounding pharmacy for an individual patient with a valid prescription, but it is not a Health Canada-approved product and has not gone through the same clinical trial process as Ozempic or Wegovy. The SOGC (Society of Obstetricians and Gynaecologists of Canada) has not issued a position statement specific to GLP-1 drugs for weight management, though the drug class is increasingly relevant to patients with polycystic ovary syndrome (PCOS) and those in perimenopause, a period when metabolic changes can accelerate weight gain. Provincial pharmacare coverage for Wegovy specifically remains limited: as of this writing, no province lists it as a standard benefit for obesity alone, though some private insurers and employer drug plans do cover it. Patients with type 2 diabetes have better access through provincial formularies for Ozempic. Online prescribing platforms operating in Canada, including Felix (a Canadian telehealth platform), Maple (a Canadian virtual care service), and Science & Humans (scienceandhumans.com), have all added GLP-1 prescribing to their services, though the drug itself still requires a pharmacy to dispense or compound it.

What changed

For years, the GLP-1 story in Canada was defined by shortage. Novo Nordisk, which manufactures both Ozempic and Wegovy, faced global supply constraints from 2022 through much of 2025. Health Canada listed semaglutide on its drug shortage database repeatedly during that period, and many patients who had started treatment were forced to stop. That supply picture has improved significantly in 2026, and the parallel growth of compounding pharmacies offering semaglutide injections at prices ranging from roughly CAD $150 to $250 per month has created a second tier of access. A CTV News report published November 2, 2026 captured both sides of this moment: patients experiencing meaningful weight loss and improved metabolic health, and others dealing with severe nausea, vomiting, muscle loss, and the psychological difficulty of stopping a drug they cannot afford long-term. The Obesity Society and the American Diabetes Association have both published guidance noting that GLP-1 drugs are intended as long-term treatments, not short courses, and that weight regain after stopping is common. Canadian clinicians are working from similar evidence.

What Canadian patients should know

GLP-1 receptor agonists work by mimicking a gut hormone that stimulates insulin release, slows gastric emptying, and reduces appetite. They are not appetite suppressants in the traditional stimulant sense. The clinical trial data for semaglutide, including the STEP trials published in the New England Journal of Medicine, showed average weight loss of around 15 percent of body weight over 68 weeks in adults with obesity. Those results were for the brand-name Wegovy at the approved 2.4 mg weekly dose. Compounded versions may use the same active ingredient, but dosing, sterility, and concentration can vary between compounding pharmacies, and there is no Health Canada-mandated equivalence testing for compounded products.

If you are considering a GLP-1 drug in Canada, a few practical points are worth knowing:

• A prescription from a licensed Canadian physician or nurse practitioner is required. Telehealth platforms like Felix and Maple can provide this, but they will still conduct a medical intake and are not obligated to prescribe if the clinical picture doesn't support it.
• If you have type 2 diabetes, ask your provincial pharmacare plan specifically about Ozempic coverage. Most provinces cover it for diabetes at some doses.
• If you are seeking it for weight management without a diabetes diagnosis, expect to pay out of pocket or through private insurance unless your province has a specific obesity program. Alberta has piloted some coverage through its Obesity Program; other provinces have not moved as far.
• Side effects are common, particularly in the first weeks of dose escalation. Nausea, vomiting, constipation, and fatigue are the most frequently reported. Rarer but more serious risks include pancreatitis and, in animal studies (not confirmed in humans at therapeutic doses), thyroid C-cell changes. The Mayo Clinic notes that patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use semaglutide.
• Muscle loss during rapid weight loss on GLP-1 drugs is a documented concern. The Endocrine Society has flagged the importance of adequate protein intake and resistance exercise for patients on these medications.

Limitations and open questions

The long-term cardiovascular and metabolic data for semaglutide are actually among the strongest in the obesity drug class, with the SELECT trial (published in the New England Journal of Medicine in 2023, involving over 17,000 participants) showing a 20 percent reduction in major cardiovascular events in adults with obesity and established cardiovascular disease. But that trial used the brand-name formulation at a specific dose. Whether compounded semaglutide produces the same outcomes is not known, because no equivalence trials have been run.

Health Canada has not yet issued formal guidance on compounded semaglutide, and the Canadian Pharmacists Association has called for clearer national standards. The SOGC has not issued a position on GLP-1 use in perimenopausal patients specifically, a gap that matters given the metabolic overlap between menopause and obesity. The Canadian Institutes of Health Research (CIHR) has funded some work on obesity pharmacotherapy, but no large Canadian-specific trial on GLP-1 generics or compounded products has reported results.

For patients already on brand-name Ozempic or Wegovy who are considering switching to a compounded version to save money, the conversation with their prescriber should include the absence of Health Canada approval for the compounded product, the variability between compounding pharmacies, and the importance of not self-adjusting doses.

This article is for informational purposes only and is not medical advice. Consult your Canadian healthcare provider about your situation.

Editorial note

Hormone Journal articles are written by our editorial team and reviewed against published clinical guidelines, with a focus on Canadian patient access. We do not promote specific clinics or providers.